Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with mild to moderate primary open-angle glaucoma (the most common type of glaucoma, where fluid doesn't drain properly from the eye)
- Your eye test results match what is expected for mild to moderate glaucoma
- You are currently using between 1 and 4 eye drop medications to lower the pressure in your eye, and your eye pressure meets the specific levels required by the trial
- You have a cataract that is affecting your vision enough to need treatment
Who may not be able to join:
- You have previously had a laser treatment for glaucoma called laser trabeculoplasty in the eye being studied
- You have previously had certain laser procedures called ECP or Micropulse laser in the eye being studied
- You have previously had a small device called an iStent or iStent Inject implanted in the eye being studied
- You have previously had a device called a Hydrus Microstent implanted in the eye being studied
- You have previously had a surgical procedure to drain fluid from the eye (such as trabeculectomy, Xen, Express, or a drainage valve) in the eye being studied
- You have previously had a procedure called canaloplasty in the eye being studied
- You have previously had a procedure called goniotomy or trabeculotomy in the eye being studied
- You have previously had a suprachoroidal stent device (such as Cypass, iStent Supra, or MINIject) implanted in the eye being studied
- You are planning to have any other eye pressure-lowering procedure at the same time as the trial surgery, other than the specific device being studied
- You have previously been treated with the iTrack device in the eye being studied (treatment in the other eye only is allowed)
- You have a type of glaucoma other than primary open-angle glaucoma, such as glaucoma caused by injury, inflammation, abnormal blood vessels, or a type present from birth (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Norbert Koerber, MD, Augencentrum Köln Ophthalmology
Phone: 800-391-2316
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Reduction in mean Intraocular Pressure (IOP) at 12 months compared to baseline; Reduction in number of glaucoma medications at 12 months compared to baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.